

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

LIGAND PHARMACEUTICALS INC
Form SC 13G
February 10, 2005

SECURITIES EXCHANGE COMMISSION

Washington, DC 20549

Under the Securities Exchange Act of 1934
(Amendment No. 3)

LIGAND PHARMACEUTICALS
(Name of Issuer)

Common
(Title of Class of Securities)

Date of Event Which Requires Filing of this Statement
December 31, 2004

Check the appropriate box to designate the rule
pursuant to which this Schedule is filed

Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

53220K207
(CUSIP NUMBER)

- 1) Name of Reporting Pioneer Global Asset Person Management S.p.A.
- | | |
|------------------------------------|------------|
| IRS Identification
No. of Above | 98-0362802 |
|------------------------------------|------------|
- 2) Check the Appropriate Box
of A Member of Group
(See Instructions)
- | | |
|-----|--|
| (a) | |
| (b) | |
- 3) SEC Use Only
- 4) Citizenship of Place of
Organization
- | | |
|-------|--|
| Italy | |
|-------|--|
- | | | |
|---|-----------------------------------|-----------|
| Number of
Shares
Beneficially Owned
by Each Reporting
Person With | (5) Sole Voting
Power | 2,865,031 |
| | (6) Shared Voting
Power | 0 |
| | (7) Sole Disposi-
tive Power | 2,865,031 |
| | (8) Shared Disposi-
tive Power | 0 |
- 9) Aggregate Amount Beneficially
Owned by Each
Reporting Person
- | |
|-----------|
| 2,865,031 |
|-----------|
- 10) Check if the aggregate Amount in Row (9) Exclude Certain Shares (See
Instructions)
- 11) Percent of Class Represented

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

By Amount in Row 9. 3.73%

12) Type of Reporting Person (See Instructions) HC

Item 1(a) Name of Issuer.
IVAX CORPORATION

Item 1(b) Address of Issuer's Principal Executive Offices:
Mr. Paul V. Maier
Chief Financial Officer
Ligand Pharmaceuticals
10275 Science Center Drive
San Diego, FL 92121

Item 2(a) Name of Person Filing:
Pioneer Global Asset Management S.p.A.

Item 2(b) Address of Principal Business Office:
Galleria San Carlo 6,
20122 Milan, Italy

Item 2(c) Citizenship:
Italy

Item 2(d) Title of Class of Securities:
Common Stock

Item 2(e) CUSIP Number:
53220K207

Item 3 The person filing this statement pursuant to Rule 13d-1(b) or 13d-2(b) is:
(Inapplicable)

Item 4. Ownership.

(a) Amount Beneficially Owned: 2,865,031

(b) Percent of Class: 3.73%

(c) Number of shares as to which such person has

- (i) sole power to vote or to direct the vote 2,865,031
- (ii) shared power to vote or to direct vote 0
- (iii) sole power to dispose or to direct disposition of 2,865,031
- (iv) shared power to dispose or to direct disposition 0

Item 5. Ownership of Five Percent or Less of a Class.

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

If this statement is being filed to report the fact that as of the date Hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check here: X

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Inapplicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported On By the Parent Holding Company.

Inapplicable.

Item 8. Identification and Classification of Members of the Group.

Inapplicable.

Item 9. Notice of Dissolution of the Group.

Inapplicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transactions having such purposes or effect.

After reasonable inquiry and to the best of my knowledge and believe, I certify that the information set forth in this statement is true, complete and correct.

February 10, 2005
Date

/s/Dario Frigerio
Name: Dario Frigerio
Title: Chief Executive Officer